Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36793   clinical trials with a EudraCT protocol, of which   6076   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients with Active Moderate to Severe Ulcerative Colitis (UC)

    Summary
    EudraCT number
    2012-002013-19
    Trial protocol
    BE   AT   IT   DE   PL  
    Global end of trial date
    25 Apr 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    05 Jan 2017
    First version publication date
    05 Jan 2017
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ACT12688
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01659138
    WHO universal trial number (UTN)
    U1111-1124-1076
    Other trial identifiers
    Study Name: FUSCIA
    Sponsors
    Sponsor organisation name
    Sanofi aventis recherche & développement
    Sponsor organisation address
    1 avenue Pierre Brossolette, Chilly-Mazarin, France, 91380
    Public contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Scientific contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    05 May 2016
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    25 Apr 2016
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To assess the induction of clinical response at Week 8 with intravenous (I.V.) SAR339658 20 mg/kg administered as 4 infusions once every 2 weeks (q2w) in subjects with active moderate to severe ulcerative colitis (UC).
    Protection of trial subjects
    Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    23 Aug 2012
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety
    Long term follow-up duration
    24 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 1
    Country: Number of subjects enrolled
    France: 1
    Country: Number of subjects enrolled
    Germany: 1
    Country: Number of subjects enrolled
    Italy: 1
    Country: Number of subjects enrolled
    Canada: 1
    Country: Number of subjects enrolled
    United States: 23
    Worldwide total number of subjects
    28
    EEA total number of subjects
    4
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    27
    From 65 to 84 years
    1
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 41 sites in 7 countries. A total of 90 subjects were screened between August 2012 and March 2014. The decision to discontinue the study was notified to investigators in March 2014 due to slow enrollment. Indeed 28 subjects were randomized by that date.

    Pre-assignment
    Screening details
    The 62 screen failures were mainly due to failure to meet the inclusion/exclusion criteria. Enrolled subjects were initially randomized according to a 1:1 ratio. Then, from April 2013, the randomization schedule was changed to 2:1 ratio (SAR339658: Placebo) and the sample size was adjusted according to protocol amendment.

    Period 1
    Period 1 title
    Double-Blind Treatment Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Placebo matched to SAR339658 infusion at Week 0, 2, 4, and 6.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Placebo for SAR339658 infusion over 60 minutes (for subjects weighing <120 kg) or 120 minutes (for subjects weighing >120 kg).

    Arm title
    SAR339658
    Arm description
    SAR339658 20 mg/kg infusion at Week 0, 2, 4, and 6.
    Arm type
    Experimental

    Investigational medicinal product name
    Vatelizumab
    Investigational medicinal product code
    SAR339658
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    SAR339658 20 mg/kg infusion over 60 minutes (for subjects weighing <120 kg) or 120 minutes (for subjects weighing >120 kg).

    Number of subjects in period 1
    Placebo SAR339658
    Started
    10
    18
    Treated
    10
    18
    Completed
    4
    13
    Not completed
    6
    5
         Sponsor's decision
    4
    4
         Adverse event
    -
    1
         Lack of efficacy
    1
    -
         Consent withdrawn by subject
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo matched to SAR339658 infusion at Week 0, 2, 4, and 6.

    Reporting group title
    SAR339658
    Reporting group description
    SAR339658 20 mg/kg infusion at Week 0, 2, 4, and 6.

    Reporting group values
    Placebo SAR339658 Total
    Number of subjects
    10 18 28
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    48.9 ± 11.9 43.6 ± 14.1 -
    Gender categorical
    Units: Subjects
        Female
    5 6 11
        Male
    5 12 17
    Baseline Total Mayo Score
    The Mayo Score is a discrete ordinal scale to assess ulcerative colitis activity. It is a composite of 4 sub-scores: Stool Frequency Sub-score, Rectal Bleeding Sub-score, Endoscopy Sub-score, and Physician's Global Assessment Sub-score (PGAS), each of which ranges from 0 (normal) to 3 (severe disease). Total score ranges from 0 (normal or inactive disease) to 12 (severe disease).
    Units: Units on a scale
        arithmetic mean (standard deviation)
    8.2 ± 1.32 8.56 ± 1.92 -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo matched to SAR339658 infusion at Week 0, 2, 4, and 6.

    Reporting group title
    SAR339658
    Reporting group description
    SAR339658 20 mg/kg infusion at Week 0, 2, 4, and 6.

    Primary: Number of Subjects with Clinical Response (Per Mayo Score) at Week 8

    Close Top of page
    End point title
    Number of Subjects with Clinical Response (Per Mayo Score) at Week 8 [1]
    End point description
    The Mayo Score is a discrete ordinal scale to assess ulcerative colitis activity. It is a composite of 4 sub-scores for stool frequency, rectal bleeding, endoscopy, and Physician's Global Assessment (PGAS), each of which ranges from 0 (normal) to 3 (severe disease). Total score ranges from 0 (normal or inactive disease) to 12 (severe disease). Clinical response per Mayo score (also known as the Disease Activity Index- DAI) was defined as a decrease in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the sub score for rectal bleeding of at least 1 point or an absolute sub score for rectal bleeding of 0 or 1 and with the endoscopic sub-score read by a central reader. Analysis was performed on intent-to-treat (ITT) population that included all randomized subjects.
    End point type
    Primary
    End point timeframe
    Baseline to Week 8
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Due to the early termination of the study, and because of the small number of randomized subjects (18 instead of 93), statistical comparison was not performed.
    End point values
    Placebo SAR339658
    Number of subjects analysed
    10
    18
    Units: subjects
    1
    4
    No statistical analyses for this end point

    Secondary: Number of Subjects with Clinical Remission (Per Mayo Score) at Week 8

    Close Top of page
    End point title
    Number of Subjects with Clinical Remission (Per Mayo Score) at Week 8
    End point description
    Clinical remission per Mayo score was defined as a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point. Analysis was performed on ITT population.
    End point type
    Secondary
    End point timeframe
    Baseline to Week 8
    End point values
    Placebo SAR339658
    Number of subjects analysed
    10
    18
    Units: subjects
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Subjects with Mucosal Healing (per Mayo Endoscopic Sub-score) at Week 8

    Close Top of page
    End point title
    Number of Subjects with Mucosal Healing (per Mayo Endoscopic Sub-score) at Week 8
    End point description
    Mucosal healing was defined as an absolute endoscopic sub-score of 0 or 1, obtained from colonoscopy (read by a central reader). Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, and mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, and erosions), 3 = Severe disease (spontaneous bleeding, ulceration). Analysis was performed on ITT population.
    End point type
    Secondary
    End point timeframe
    Baseline to Week 8
    End point values
    Placebo SAR339658
    Number of subjects analysed
    10
    18
    Units: subjects
    0
    2
    No statistical analyses for this end point

    Secondary: Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 4 and Week 8

    Close Top of page
    End point title
    Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 4 and Week 8
    End point description
    The IBDQ is a self-administered 32-item questionnaire that evaluates the disease specific quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The total IBDQ score is the sum of the responses to the individual questions and can range from 32 to 224; a higher scores indicating a better quality of life. Analysis was performed on ITT population. Here, 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4 and Week 8
    End point values
    Placebo SAR339658
    Number of subjects analysed
    10
    18
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 4 ( n=6,13 )
    21.17 ± 22.75
    28.46 ± 40.76
        Week 8 ( n=6,18 )
    14.83 ± 12.32
    12.28 ± 27.39
    No statistical analyses for this end point

    Secondary: Change from Baseline in Quality of Life Measured by 36-Item Short-Form Health Survey (SF-36) Scores at Week 4 and Week 8

    Close Top of page
    End point title
    Change from Baseline in Quality of Life Measured by 36-Item Short-Form Health Survey (SF-36) Scores at Week 4 and Week 8
    End point description
    SF-36 is a self-rated 36-item questionnaire measuring health-related quality of life across eight domains: physical function, role limitations due to physical problems, pain, and general health perception (physical component), vitality, social function, role limitations due to emotional problems, and mental health (mental component). Eight sub-scale scores are obtained by computerizing items scores, and can range from 0 (maximum disability) to 100 (no disability). Component scores are mean average of sub-scale scores. Analysis was performed on ITT population. Here, 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4 and Week 8
    End point values
    Placebo SAR339658
    Number of subjects analysed
    10
    18
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Physical component score at Week 4 (n=6, 13)
    4.5 ± 7.5
    0.4 ± 5.2
        Physical component score at Week 8 (n=7, 17)
    2.6 ± 3.9
    -0.1 ± 4.9
        Mental component score at Week 4 (n=6, 13)
    2.3 ± 6.4
    2.8 ± 8.9
        Mental component score at Week 8 (n=7, 17)
    0 ± 7.3
    0.4 ± 6.4
    No statistical analyses for this end point

    Secondary: Change from Baseline in Partial Mayo Score at Week 4 and Week 6

    Close Top of page
    End point title
    Change from Baseline in Partial Mayo Score at Week 4 and Week 6
    End point description
    The partial Mayo score is calculated as a sum of three sub-scores: stool frequency sub-score, rectal bleeding sub-score and Physician's Global Assessment sub-score. It is in a range from 0-9 points; higher partial Mayo scores indicate more severe disease. Analysis was performed on ITT population. Here, 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4 and Week 6
    End point values
    Placebo SAR339658
    Number of subjects analysed
    10
    18
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 4 ( n=6,13 )
    -1.67 ± 1.86
    -0.85 ± 2.67
        Week 6 ( n=5,13 )
    -1.8 ± 2.05
    -0.62 ± 2.26
    No statistical analyses for this end point

    Other pre-specified: Long Term Safety Follow-up: Number of Subjects who experienced Opportunistic or Progressive Multifocal Leukoencephalopathy (PML)

    Close Top of page
    End point title
    Long Term Safety Follow-up: Number of Subjects who experienced Opportunistic or Progressive Multifocal Leukoencephalopathy (PML)
    End point description
    Subjects were contacted by phone at 3, 6, 12, 18 and 24 months post-treatment. During the phone contact, subject was asked specific questions regarding any new signs or symptoms indicative of infection. Any positive findings on questioning was expeditiously referred to a physician for additional evaluation. If any abnormal signs and symptoms are observed or identified, the subject was subsequently referred to an infectious disease specialist or a neurologist for a complete assessment. Analysis included all subjects who received at least one dose of study drug and consented in participating in the post-treatment long term safety follow-up, excluding those who enrolled in the long-term open-label extension study LTS12593 (EudraCT no. 2013-001012-30). For the lasts, the long term safety follow-up results are provided with the LTS12593 results.
    End point type
    Other pre-specified
    End point timeframe
    Up to 24 months after the last dose of investigational medicinal product (IMP)
    End point values
    Placebo SAR339658
    Number of subjects analysed
    4
    8
    Units: subjects
    0
    0
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All Adverse Events (AE) were collected from signature of the informed consent form up to the last visit (Week 14 [Week 30 for German subjects]) or enrollment in the LTS12593 (2013-001012-30) study regardless of seriousness or relationship to study drug.
    Adverse event reporting additional description
    Reported AEs and deaths are treatment-emergent that is AEs that developed/worsened and deaths that occurred during the ‘on treatment period’ (from the first dose of study drug up to the last visit in the study or enrollment in the LTS12593 study).
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.1
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects exposed to Placebo (mean exposure of 41 days).

    Reporting group title
    SAR339658
    Reporting group description
    Subjects exposed to SAR339658 (mean exposure of 48 days).

    Serious adverse events
    Placebo SAR339658
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Gastrointestinal disorders
    Colitis Ulcerative
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo SAR339658
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    5 / 10 (50.00%)
    10 / 18 (55.56%)
    Injury, poisoning and procedural complications
    Infusion Related Reaction
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Procedural Headache
         subjects affected / exposed
    0 / 10 (0.00%)
    2 / 18 (11.11%)
         occurrences all number
    0
    2
    Procedural Nausea
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    2
    0
    Investigations
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Blood Alkaline Phosphatase Increased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Gamma-Glutamyltransferase Increased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Urine Analysis Abnormal
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    1
    Migraine
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Muscle Contractions Involuntary
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    2
    General disorders and administration site conditions
    Chest Discomfort
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    1
    Fatigue
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    1
    Pyrexia
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Abdominal Pain
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Anal Fissure
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    Anal Pruritus
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Anorectal Discomfort
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    Aphthous Stomatitis
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    Diarrhoea
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Nausea
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    1
    Vomiting
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Acne
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Erythema
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Back Pain
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Lupus-Like Syndrome
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Infections and infestations
    Fungal Skin Infection
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Folliculitis
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    Furuncle
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    Nasopharyngitis
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    Influenza
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    2
    0
    Sinusitis
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    2
    0
    Urinary Tract Infection
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    Upper Respiratory Tract Infection
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    20 Mar 2012
    It included following changes: - The inclusion criteria was modified to focus the study target population to those who failed treatment with immunosuppressant and or biological medications. - Modified information on the risk of PML observed with other immunomodulatory medications in the protocol and in the whole slide imaging (WSI). - Clarified the signs and symptoms of PML. - A post study follow-up was included in the form of a phone call at 3 months and 6 months from the end of treatment to question the subjects regarding the presence of any neurological signs or symptoms or symptoms of other potential adverse events and refer the subject to specialist if needed. - Added monitoring for a potential increase in bleeding (eg. petechiae, mucosal bleeding). - Further instructions on the infusion of study medications and potential allergic reactions were provided. - Erythrocyte sedimentation rate (ESR) testing was removed. - Some of the laboratory testings were clarified.
    16 Jul 2012
    It included following changes: - Baseline testing for John Cunningham Virus (JCV) antibody at screening and at Week 14 was included. - Added that the results of the baseline JCV antibody test would be provided to the subject and that the subject would be given the option to withdraw from the study before they received any treatment. - Added that upon subsequent JCV antibody testing at Week 14, the subject would also be informed of their antibody status as soon as results were available. - Added that subjects would be informed that the risk of developing PML might be higher for those who were antibody positive, based on data from another drug in the class (natalizumab) and that subjects who were JCV antibody negative were still at risk for the development of PML. - After the 3 and 6 months post treatment follow-up additional follow up at 12, 18 and 24 months post treatment follow-up was added to better clarify features to enhance the completeness of follow-up. - The inclusion criteria was modified to include a definition of both inadequate response to immunosuppressants and intolerance to immunosuppressants; and to include a definition of both inadequate response to Tumor necrosis factor (TNF)-alpha antagonists and intolerance to TNF-alpha antagonists. - Additional PK testing post treatment was added. - The screening period was extended from 2 weeks to 3 weeks. - An additional blood test at Week 14 for CD4/CD8 ratio and CD19, CD34 was added. - Geographic region (North America, Western Europe and Eastern Europe) was added as a randomization stratification factor in addition to prior anti-TNF alpha therapy. - Geographic region was added as a stratification factor in the supportive Cochran-Mantel-Haenszel test. - Specific cytokines measurement at Week 0 and Fluorescence-activated cell sorting (FACS) assay measurement at Week 8 were removed.
    25 Jan 2013
    It included following changes: - Clarified that only subjects who were JCV antibody negative at baseline would be retested at Week 14. - Clarified that the QuantiFERON TB Gold test could be repeated in case the result was indeterminate or believed to be false positive test. - Clarified that subjects could have flexible sigmoidoscopy at screening if a colonoscopy was done within the last 12 months and also clarified that subjects could have a flexible sigmoidoscopy at Week 8 (end of treatment). - The randomization ratio was changed from 1:1 to 2:1 to increase the probability of receiving the active treatment. As a result, the sample size was increased by 9 subjects. - A section was added to explain that subjects could be rescreened once at the discretion of investigator. - The screening period was increased by 1 week.
    12 Apr 2013
    - Added the possibility for subjects who had completed the study treatment period in the ACT trial to transition to a long-term open-label extension safety study LTS12593. - Removed CD4/CD8<1 as an exclusion criterion but continued to evaluate and monitor. - Clarified and simplified the safety reporting and ensured the key important events would be reported and analyzed in an expedited manner.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The sample size was much smaller than the planned because the study was terminated early due to slow enrollment.
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA